

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.543 / 0206-UTL-9

APPLICATION NO.

09/719,410

APPLICANTS

Burkhard GÖKE *et al.*

FILING DATE

December 12, 2000

GROUP

1653

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AF1						Yes No
	AG1						Yes No
	AH1						Yes No
	AI1						Yes No
	AJ1						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AM	AK1	Byrne <i>et al.</i> , "Glucagon-Like Peptide-1 Improves the Ability of the $\beta$ -Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance", <u>Diabetes</u> , Vol. 46, Supplement (1), page 33A, Abstract 0127 (1997)
AM	AL1	Byrne <i>et al.</i> , "GLP-1 Improves First Phase Insulin Secretion without Altering Insulin Sensitivity in Subjects with Impaired Glucose Tolerance", <u>Diabetes</u> , Vol. 47, Supplement (1), page A192, Abstract 0744 (1998)
AM	AM1	Byrne & Göke, "Human Studies with Glucagon-like-peptide-1: Potential of the Gut Hormone for Clinical Use", <u>Diabetic Medicine</u> , Vol. 13, pp. 854-860 (1996)
AM	AN1	Wang <i>et al.</i> , "Glucagon-like Peptide-1 Can Reverse the Age-related Decline in Glucose Tolerance in Rats", <u>The Journal of Clinical Investigation</u> , Vol. 99, No. 22, pp. 2883-2889 (1997)
	AO1	
	AP1	


EXAMINER

Abdel A. Mohamed

DATE CONSIDERED

6/21/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.543 / 0206-UTL-9

APPLICATION NO.

09/719,410

APPLICANTS

Burkhard GÖKE *et al.*

FILING DATE

December 12, 2000

GROUP

1653

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AAI						
	ABI						
	ACI						
	ADI						
	AEI						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AFI						Yes No
	AGI						Yes No
	AHI						Yes No
	AII						Yes No
	AJI						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<del>AKI</del>	<del>D'ALESSIO <i>et al.</i>, "Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons", <i>The Journal of Clinical Investigation</i>, Vol. 97, No. 1, pp. 133-138 (1996)</del>
AM	AL1 European Search Report published January 12, 2005 in European Patent Application No. 04075402.0
<del>AMI</del>	<del>RITZEL <i>et al.</i>, "A synthetic glucagon-like peptide-1 analog with improved plasma stability", <i>Journal of Endocrinology</i>, Vol. 159, pp. 93-102 (1998)</del>
<del>ANI</del>	<del>SCHIRRA <i>et al.</i>, "Exendin(9-39)amide is an Antagonist of Glucagon-like Peptide-1(7-36)amide in Humans", <i>J. Clin. Invest.</i>, Vol. 101, No. 7, pp. 1421-1430 (1998)</del>
AOI	The crossed references have been considered on PTO-1449 submitted on 02/22/05. See Advisory Action of 04/20/05
API	

EXAMINER

Abdel A. Mohamed

DATE CONSIDERED

6/21/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.